Humacyte Form 4 details 311,100 stock options for CEO Niklason

Rhea-AI Filing Summary

Humacyte, Inc. (HUMA) reported a stock option award to its President, CEO and Director, Laura E. Niklason. On November 16, 2025, she was granted stock options to purchase 311,100 shares of Humacyte common stock at an exercise price of $1.23 per share, expiring on November 16, 2035. The options vest in three equal installments: one-third becomes exercisable on February 14, 2026, another third on November 16, 2026, and the final third on November 16, 2027. Following this grant, she holds these derivative securities directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Niklason Laura E

(Last) (First) (Middle)

2525 EAST NORTH CAROLINA HIGHWAY 54

(Street)

DURHAM NC 27713

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Humacyte, Inc. [ HUMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, CEO and Director

3. Date of Earliest Transaction (Month/Day/Year)
11/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$1.23	11/16/2025		A		311,100		(1)	11/16/2035	Common Stock	311,100	$0	311,100	D

Explanation of Responses:

1. The first 1/3 of the option becomes exercisable on February 14, 2026, after which 1/3 of the option will become exercisable on November 16, 2026, and the remaining 1/3 of the option will become exercisable on November 16, 2027.

Remarks:

	/s/ Laura E. Niklason by Dale A. Sander as Attorney-in-Fact	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Humacyte (HUMA) disclose in this Form 4 filing?

Humacyte disclosed a stock option grant to its President, CEO and Director, Laura E. Niklason, covering 311,100 shares of common stock.

What are the key terms of Laura Niklason’s Humacyte stock options?

The stock options give Laura Niklason the right to buy 311,100 shares of Humacyte common stock at an exercise price of $1.23 per share, with an expiration date of November 16, 2035.

How do the Humacyte stock options granted on November 16, 2025 vest?

The options vest in three equal parts: the first one-third on February 14, 2026, the second one-third on November 16, 2026, and the final one-third on November 16, 2027.

What type of security is reported for Humacyte CEO Laura Niklason?

The filing reports stock options (right to buy) as derivative securities linked to Humacyte common stock.

How many Humacyte derivative securities does Laura Niklason hold after this transaction?

After the reported transaction, Laura Niklason beneficially owns 311,100 stock options, held in direct ownership form.

Does this Humacyte Form 4 indicate a purchase or sale of common shares?

No common shares were reported as bought or sold; the filing reports the grant of stock options that may be exercised into common stock in the future.